Lonza Group AG (LONN.SW)

510,20 -12,20 (-2,34%) Alla chiusura: 05:30PM CEST

Lonza Group AG

Muenchensteinerstrasse 38
Basel 4002
Switzerland
41 61 316 81 11
https://www.lonza.com

Settore/i: Healthcare
Settore: Diagnostics & Research
Impiegati a tempo pieno: 18.000

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Albert M. Baehny	Interim CEO & Chairman	410,69k	N/D	1952
Mr. Philippe Deecke	Chief Financial Officer	N/D	N/D	1972
Ms. Maria Soler Nunez	Head of Group Operations	N/D	N/D	1969
Mr. Dirk Oehlers	Vice President of Investor Relations	N/D	N/D	N/D
Mr. Andreas Bohrer	Group General Counsel & Company Secretary	N/D	N/D	N/D
Ms. Kim Harrelson	Head of Ethics & Compliance, ERM and Corporate Responsibility	N/D	N/D	N/D
Ms. Victoria Morgan	Head of External Communications	N/D	N/D	N/D
Ms. Jennifer Clancy	Senior Director of Global Marketing	N/D	N/D	N/D
Ulrike Kaeppler	Chief Human Resources Officer	N/D	N/D	N/D
Dr. Matthias Hofmann	Head of Corporate Environment, Health, Safety & Global Sustainability	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in CHF.

Descrizione

Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing. The Small Molecules segment operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. This segment also supports customers across various aspects of design, development, and manufacturing, including particle engineering and drug product packaging. The Cell & Gene segment develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies; offers contract development and manufacturing services, and regulatory support for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. This segment also provides Cocoon platform, a closed automated system for patient-scale cell therapy manufacturing; and specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. The Capsules & Health Ingredients segment offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.

Governance aziendale

L'ISS Governance QualityScore di Lonza Group AG al 1 aprile 2024 è 3. I criteri di valutazione fondamentali sono revisione: 5; Consiglio di Amministrazione: 5; diritti degli azionisti: 1; retribuzione: 1.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.